Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for Tough-to-Treat endometrial cancer

NCT ID NCT05156268

First seen Apr 29, 2026 · Last updated Apr 29, 2026

Summary

This study tested whether combining two drugs, pembrolizumab and olaparib, can help people with endometrial cancer that has come back or not gone away. The trial included 26 adults with specific types of this cancer. Researchers measured how many participants' tumors shrank and tracked side effects to see if the treatment is safe and effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Suffolk-Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.